Protagonist Therapeutics, Inc. (PTGX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTGX POWR Grades
- Value is the dimension where PTGX ranks best; there it ranks ahead of 54.47% of US stocks.
- PTGX's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
- PTGX ranks lowest in Sentiment; there it ranks in the 1st percentile.
PTGX Stock Summary
- With a price/sales ratio of 27.03, Protagonist Therapeutics Inc has a higher such ratio than 92.16% of stocks in our set.
- The volatility of Protagonist Therapeutics Inc's share price is greater than that of 91.37% US stocks with at least 200 days of trading history.
- Protagonist Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -34.78%, greater than the shareholder yield of just 8.37% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Protagonist Therapeutics Inc, a group of peers worth examining would be MGNX, XENE, ORMP, IMGN, and SGMO.
- Visit PTGX's SEC page to see the company's official filings. To visit the company's web site, go to www.protagonist-inc.com.
PTGX Valuation Summary
- PTGX's price/earnings ratio is -28.3; this is 177.53% lower than that of the median Healthcare stock.
- Over the past 62 months, PTGX's price/sales ratio has gone NA NA.
- Over the past 62 months, PTGX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for PTGX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PTGX | 2021-08-31 | 84.7 | 6.5 | -28.3 | -26.1 |
| PTGX | 2021-08-30 | 81.7 | 6.2 | -27.3 | -25.0 |
| PTGX | 2021-08-27 | 83.6 | 6.4 | -27.9 | -25.7 |
| PTGX | 2021-08-26 | 82.4 | 6.3 | -27.5 | -25.3 |
| PTGX | 2021-08-25 | 85.7 | 6.5 | -28.6 | -26.4 |
| PTGX | 2021-08-24 | 86.8 | 6.6 | -29.0 | -26.7 |
PTGX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PTGX has a Quality Grade of D, ranking ahead of 13.72% of graded US stocks.
- PTGX's asset turnover comes in at 0.088 -- ranking 275th of 677 Pharmaceutical Products stocks.
- RGNX, ACOR, and ORGO are the stocks whose asset turnover ratios are most correlated with PTGX.
The table below shows PTGX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.088 | 1 | -0.513 |
| 2021-03-31 | 0.117 | 1 | -0.538 |
| 2020-12-31 | 0.127 | 1 | -0.678 |
| 2020-09-30 | 0.140 | 1 | -0.800 |
| 2020-06-30 | 0.100 | 1 | -0.977 |
| 2020-03-31 | 0.016 | 1 | -1.147 |
PTGX Stock Price Chart Interactive Chart >
PTGX Price/Volume Stats
| Current price | $18.00 | 52-week high | $50.54 |
| Prev. close | $15.47 | 52-week low | $12.80 |
| Day low | $15.34 | Volume | 2,955,500 |
| Day high | $18.03 | Avg. volume | 581,278 |
| 50-day MA | $44.49 | Dividend yield | N/A |
| 200-day MA | $33.18 | Market Cap | 855.92M |
Protagonist Therapeutics, Inc. (PTGX) Company Bio
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California.
Latest PTGX News From Around the Web
Below are the latest news stories about Protagonist Therapeutics Inc that investors may wish to consider to help them evaluate PTGX as an investment opportunity.
Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) InvestorsRADNOR, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) (“Protagonist”). Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from its proprietary technology platform. Protagonist’s pipe |
Protagonist Therapeutics (PTGX) Moves 18.2% Higher: Will This Strength Last?Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Protagonist Therapeutics, Inc. - PTGXNew York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTGX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.The investigation concerns whether Protagonist and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for informa |
Why Protagonist Therapeutics Stock Plunged TodayShares of Protagonist Therapeutics (NASDAQ: PTGX) were plunging 26.3% as of 3:39 p.m. EDT on Monday. The big decline came after the company announced that the U.S. Food and Drug Administration has placed a clinical hold on studies evaluating rusfertide. Protagonist was testing the drug in a phase 2 study targeting treatment of polycythemia vera and other blood disorders. |
PTGX Stock: Why Protagonist Therapeutics Is Plunging 60% TodayToday, investors in Protagonist Therapeutics and PTGX stock have seen an absolutely massive decline due to an FDA hold of its clinical trial. |
PTGX Price Returns
| 1-mo | -63.76% |
| 3-mo | -58.73% |
| 6-mo | -33.85% |
| 1-year | -11.94% |
| 3-year | 107.13% |
| 5-year | 5.88% |
| YTD | -10.71% |
| 2020 | 185.96% |
| 2019 | 4.75% |
| 2018 | -67.64% |
| 2017 | -5.41% |
| 2016 | N/A |
Loading social stream, please wait...